Oritavancin
Glycopeptide Antibacterials
Sold as Ramvocid · ORITINIV · Tenkasi (previously…
- Drug class
- Glycopeptide Antibacterials
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 5
Overview
Oritavancin is an active pharmaceutical ingredient in the Glycopeptide Antibacterials group (J01XA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | May 29, 2026 |
| EU European Union | EMA | 1 | November 20, 2024 |
| CA Canada | Health Canada | 2 | December 18, 2025 |
GBUnited Kingdom· MHRA
2 products
Uses
1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
How to take
EUEuropean Union· EMA
1 product
Uses
1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
How to take
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Oritavancin. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB162390060 · revised April 17, 2026
- [2]European Medicines Agency · EMEA/H/C/003785 · revised November 20, 2024
- [3]Health Canada (DPD) · 02561042 · revised December 18, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.